Hongbo Huang Selected Research

Hongbo Huang Research Topics

Disease

9	Neoplasms (Cancer) 03/2024 - 02/2012
5	Lung Neoplasms (Lung Cancer) 01/2022 - 04/2018
4	COVID-19 10/2022 - 01/2021
2	Glioblastoma (Glioblastoma Multiforme) 03/2024 - 01/2020
2	Cardiovascular Diseases (Cardiovascular Disease) 10/2023 - 01/2022
2	Breast Neoplasms (Breast Cancer) 10/2023 - 01/2018
2	Atherosclerosis 01/2022 - 04/2017
2	Communicable Diseases (Infectious Diseases) 09/2021 - 01/2017
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020 - 07/2018
2	Pain (Aches) 01/2020 - 04/2018
1	Glioma (Gliomas) 03/2024
1	Aortic Dissection 10/2023
1	Unilateral Breast Neoplasms 10/2023
1	Diabetic Cardiomyopathies 04/2023
1	Fibrosis (Cirrhosis) 04/2023
1	Pathologic Constriction (Stenosis) 01/2022
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022
1	Spontaneous Coronary Artery Dissection 01/2022
1	Stillbirth 05/2021
1	Proteinuria 05/2021
1	Pre-Eclampsia (Preeclampsia) 05/2021
1	Leukopenia 03/2021
1	Lymphopenia (Lymphocytopenia) 03/2021
1	Diarrhea 01/2021
1	Anorexia 01/2021
1	Adenocarcinoma 01/2020
1	Lymphatic Metastasis 01/2020
1	Pleural Effusion (Pleural Effusions) 01/2020
1	Subcutaneous Emphysema 01/2020
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 02/2019
1	Residual Neoplasm 07/2018
1	Tuberculosis (Tuberculoses) 01/2017
1	Neoplasm Metastasis (Metastasis) 07/2016
1	Cataract (Cataracts) 05/2015

Drug/Important Bio-Agent (IBA)

3	Proteins (Proteins, Gene)FDA Link 03/2024 - 01/2020
3	Biomarkers (Surrogate Marker)IBA 10/2023 - 01/2022
2	C-Reactive ProteinIBA 03/2021 - 01/2021
2	CholesterolIBA 01/2020 - 04/2017
2	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 03/2015
1	Temozolomide (Temodar)FDA LinkGeneric 03/2024
1	1,3,4,6- tetra- O- acetyl- 2- azido- 2- deoxyglucopyranose (TAAD)IBA 10/2023
1	Small Cytoplasmic RNAIBA 10/2023
1	Glucose (Dextrose)FDA LinkGeneric 04/2023
1	GlycogenIBA 04/2023
1	VaccinesIBA 10/2022
1	AntibodiesIBA 10/2022
1	Immunoglobulins (Immunoglobulin)IBA 10/2022
1	Complementarity Determining Regions (Complementarity Determining Region)IBA 10/2022
1	Deoxyribonuclease (Pyrimidine Dimer)IBA 01/2022
1	EnzymesIBA 01/2022
1	MycotoxinsIBA 01/2022
1	beauvericinIBA 01/2022
1	Sterol O-AcyltransferaseIBA 01/2022
1	zedoarondiolIBA 01/2022
1	HLA-DRB1*04 antigenIBA 09/2021
1	HLA-B Antigens (HLA-B)IBA 09/2021
1	HLA Antigens (Human Leukocyte Antigens)IBA 09/2021
1	Indicators and Reagents (Reagents)IBA 05/2021
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 03/2021
1	Nucleic AcidsIBA 01/2021
1	Complement C3 (C3 Complement)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	ThymalfasinIBA 01/2021
1	grincamycin BIBA 01/2020
1	pitavastatin (itavastatin)FDA Link 01/2020
1	KinesinsIBA 01/2020
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020
1	arginyl-glycyl-aspartic acidIBA 01/2019
1	cupric sulfide (CuS)IBA 01/2019
1	IonsIBA 01/2019
1	DNA (Deoxyribonucleic Acid)IBA 07/2018
1	Complement System Proteins (Complement)IBA 07/2018
1	Cell-Free Nucleic AcidsIBA 07/2018
1	fibrin fragment D (D-dimer)IBA 04/2018
1	Analgesics (Analgesic Drugs)IBA 04/2018
1	Estrogen ReceptorsIBA 01/2018
1	Estradiol (Delestrogen)FDA LinkGeneric 01/2018
1	Apolipoproteins E (ApoE)IBA 04/2017
1	Antitubercular AgentsIBA 01/2017
1	iopromide (Ultravist)FDA Link 07/2016
1	KetosesIBA 03/2015
1	CD13 Antigens (Alanine Aminopeptidase)IBA 03/2014
1	Molecular Probes (Molecular Probe)IBA 03/2014
1	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 03/2014

Therapy/Procedure

3	Length of Stay 03/2021 - 01/2020
2	Drug Therapy (Chemotherapy) 03/2024 - 02/2019
2	Therapeutics 01/2019 - 03/2014
1	Prophylactic Mastectomy 10/2023
1	Mastectomy (Mammectomy) 10/2023
1	Stents 01/2022
1	Conservative Treatment 01/2022
1	Induced Labor 05/2021
1	Catheters 01/2020
1	Adjuvant Chemotherapy 02/2019
1	Lasers (Laser) 01/2019
1	Photothermal Therapy 01/2019
1	Thoracotomy 04/2018
1	Perioperative Period 04/2018
1	Ligation 04/2017
1	Phacoemulsification 05/2015